A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 28 Jul 2009 Actual patient number (54) added as reported by ClinicalTrials.gov.
- 20 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov. The actual end date was April 2008.
- 13 Sep 2005 New trial record.